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COST OF HOSPITALIZATION FOR THORACIC 
SURGERY IN PATIENTS WITH LUNG CANCER
IN GREECE
Leftakis A1, Geitona M2
1Thoracic Diseases SOTIRIA Hospital, Athens, Greece; 
2National School of Public Health, Athens, Greece
OBJECTIVES: To estimate the cost of hospitalization for
thoracic surgery in patients with lung cancer, admitted to
the Intensive Care Unit (ICU) of “SOTIRIA” General
District Hospital in Athens.
METHODS: The chosen ICU is part of one of the largest
specialized thoracic disease hospitals in Greece. Methodol-
ogy is based on a retrospective study of patient records
over a six-month period from September 1st 1997 to Feb-
ruary 28th 1998. The sample consisted of 95 patients.
Clinical data were derived from patients’ medical records,
while administrative, economic and other data came from
the Hospital’s administrative/financial department. Cost
analysis is based on the cost of personnel, supplies, medi-
cation, laboratory and imaging tests, cost of infrastructure,
hotel services and various on-site costs. Descriptive statisti-
cal analysis and frequencies were determined for the age,
gender, hospital and length of stay (LOS-pre and postoper-
ative inpatient stay) in ICU, severity of illness, resource
consumption and ICU outcome (survival or death). All
costs are reported in 1998 US dollars.
RESULTS: 218 patients from the five “SOTIRIA” hospi-
tal surgical departments were admitted to the ICU, 95 of
whom (43.6%) were patients who underwent surgery for
lung cancer. They had a total of 2,011 inpatient days and
276 inpatient days in the ICU. LOS in the hospital was
21.1 days and 2.9 days in the ICU. LOS for the preopera-
tive period was 7.9 days and 10.3 days postoperative.
Total patient-hospitalization costs in the ICU are esti-
mated at US$ 191,065 (pre) and US$ 2,011(post) per pa-
tient. Major cost components are salaries of personnel
(41.7%), diagnostic tests (23%), and medication (15%).
Mean hospitalization cost for a thoracic surgery patient
with lung cancer is estimated at US$ 6,958.
CONCLUSIONS: Economic analysis could substantially
contribute to the costing of diseases and would enable
Greek policy makers to obtain the information required
for their decision-making.
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COST-EFFECTIVENESS OF SENTINEL LYMPH 
NODE MAPPING AND ADJUVANT INTERFERON 
THERAPY FOR STAGE II MELANOMA
Wilson LS, Reyes CM, Lu C, Lu M, Yen C
University of California San Francisco, San Francisco, CA, USA
OBJECTIVE: Clinical studies have demonstrated that
high dose adjuvant interferon therapy improves disease-
free and overall survival among high-risk (stage IIb and
stage III) melanoma patients. Sentinel lymph node map-
ping (SLM) identifies metastasis and more accurately dif-
ferentiates between stage II patients at high risk, who
then might benefit most from adjuvant interferon ther-
apy. We analyzed the cost-effectiveness of first testing
with sentinel lymph node mapping (SLM) and then treat-
ing with adjuvant interferon (IFN) therapy for stage II
melanoma.
METHODS: We used a decision analytic model to com-
pare four strategies for stage II patients after surgical ex-
cision of their melanoma: 1) treat all with low dose IFN;
2) test first with SLM and then treat only those with pos-
itive micrometastases with high dose IFN; 3) test first
with SLM and treat positives with high dose and nega-
tives with low dose IFN (test and treat appropriately); 4)
treat no one. Treatment, toxicity, follow-up and relapse
costs were included. The primary outcome was cost per
quality adjusted life year (QALY)
RESULTS: Our analyses show that it is cost-effective to
first test with SLM and treat appropriately compared to
treating all with low dose IFN ($12,400/QALY). More-
over, it is cost-effective to test and treat appropriately
versus testing and only treating some with high dose
($27,100/QALY). It is also more cost-effective to test and
treat appropriately compared to no treatment ($31,700/
QALY).
CONCLUSION: Appropriate dosing of IFN therapy
based on the results of sentinel lymph node mapping is a
cost-effective strategy for stage II melanoma patients.
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THE RELATIONSHIP OF AGE AND DURATION 
OF HORMONAL THERAPY USE AMONG 
PATIENTS DIAGNOSED WITH CANCER
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Stolshek B1, Hersom K2, Pelletier E2, Delgado D1
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OBJECTIVE: The utilization of LHRH agonists and anti-
androgens in prostate cancer has resulted from both their
availability and the substantial regret of patients follow-
ing orchiectomy. Previously unavailable, this study de-
scribes hormonal therapy resource use by age group and
duration from a large payer claims database.
METHODS: Male patients were identified in the Synergy
data warehouse from 03/1999 to 07/2000 with age 40,
a claim for prostate cancer specific LHRH agonist medi-
cation, any additional prescription claim, and continuous
medical and pharmacy enrollment. New cases of LHRH
agonist monotherapy (MONO) or combination therapy
with anti-androgen (CAB) were defined as no MONO or
CAB during the 4 months prior to 3/1999. Therapy
groups were stratified by age group (65 (younger) and
65 (older)) and followed until 07/2000. Descriptive sta-
tistics were used to summarize the data.
RESULTS: 582 younger patients and 878 older patients
were identified. 93.0% of the younger patients had pri-
vate insurance compared to 28.2% government and
71.8% private insurance in the older patients. Average
